FLT3 and acute myeloid leukemia: First, the proposed method focuses only on the monotherapy setting, while the practical treatments of AML are usually compound combinations, e.g., the addition of FLT3 inhibitors (gilteritinib, sorafenib, quizartinib, and others) to the intensive chemotherapy or the combination of IDH inhibitors (ivosidenib and enasidenib) and venetoclax7.